david xu | PARTNER | new york

As former Head of the Specialty Products Franchise at Novartis (US), Head of Marketing and New Product Planning at Purdue Pharma (US), and CEO of the Novartis R&D Center in Suzhou, David brings deep expertise spanning drug R&D, manufacturing, marketing, and sales. During his tenure as CBO at Viva Biotech, David led investments in over 50 biotech companies, with more than 10 successful exits.

  • •DTx Pharma: Extrahepatic siRNA delivery platform (acquired by Novartis)

    •Dogma: The world’s first small-molecule PCSK9 inhibitor (acquired by AstraZeneca)

    •Bonti: Novel botulinum toxin (acquired by Allergan)

    •Totient: AI-guided endogenous antibody discovery platform (acquired by AbSci)

    •Nerio Therapeutics: FIC heart failure therapy (acquired by Boehringer Ingelheim), etc.

  • •B.S. in Chemistry, Peking University

    •Ph.D. in Chemistry, University of California, Los Angeles (UCLA)

    •Postdoctoral Fellow, The Scripps Research Institute (TSRI)

    •M.B.A., The Wharton School, University of Pennsylvania